Cantab, Pfizer deal

The companies will develop CNTBY's Disc-Virus vaccine technology to prevent veterinary viral diseases.

Up-front payments from Pfizer total $4 million, including an $800,000 license fee and an 8 percent equity investment in CNTBY through the purchase of 800,000 shares at £2.50 (US$4). Pfizer will provide further license fees, contract development revenues and milestones, which could exceed $6 million. CNTBY also would receive royalties. ...